Boyella VD, Nicastri AD, Bergasa NV

Idioma: Español
Referencias bibliográficas: 23
Paginas: 221-225
Archivo PDF: 139.94 Kb.

FRAGMENTO

Sin resumen

REFERENCIAS (EN ESTE ARTÍCULO)

1. Roskams T, de Vos R, Joost JVDO, Desmet V. Cells with neuroendocrine features in regenerating human liver. APMIS Suppl 1991; 23: 32-39.

2. Roskams T, van den Oord J, De Vos R, Desmet V. Neuroendocrine features of reactive bile ductules in cholestatic liver disease. Am J Pathol 1990; 13: 1019-1025.

3. Bergasa NV, Sabol SL, Young WSD, Kleiner DE, Jones EA. Cholestasis is associated with preproenkephalin mRNA expression in the adult rat liver. Am J Physiol 1995; 268: G346-354.

4. Bergasa NV, Liau S, Homel P, Ghali V. Hepatic Met-enkephalin immunoreactivity is enhanced in primary biliary cirrhosis. Liver 2002; 22: 107-113.

5. Nicoll J, Axiotis CA, Bergasa NV. The delta opioid receptor 1 is expressed by proliferating bile ductules in rats with cholestasis: implications for the study of liver regeneration and malignant transformation of biliary epithelium. Med Hypotheses 2005; 65: 1099-1105.

6. Marzioni M, Alpini G, Saccomanno S, de Minicis S, Glaser S, Francis H, Trozzi L, et al. Endogenous opioids modulate the growth of the biliary tree in the course of cholestasis. Gastroenterology 2006; 130: 1831-1847.

7. Zagon IS, Rhodes RE, McLaughlin PJ. Localization of enkephalin immunoreactivity in diverse tissues and cells of the developing and adult rat. Cell Tissue Res 1986; 246: 561-565.

8. Polakiewicz RD, Rosen H. Regulated expression of proenkephalin A during ontogenic development of mesenchymal derivative tissues. Mol Cell Biol 1990; 10: 736-742.

9. Rosen H, Bar-Shavit Z. Dual role of osteoblastic proenkephalin derived peptides in skeletal tissues. J Cell Biochem 1994; 55: 334-339.

10. McLaughlin PJ, Allar MA. Preproenkephalin gene expression and [Met5]-enkephalin levels in the developing rat heart. Brain Res Mol Brain Res 1998; 60: 160-167.

11. Zagon IS, Wu Y, McLaughlin PJ. Opioid growth factor and organ development in rat and human embryos. Brain Res 1999; 839: 313-322.

12. Marshall W. From cells on up: Symposium on Cell Biology of Development and Disease. EMBO Rep 2003; 4: 556-559.

13. Giannelli G, Quaranta V, Antonaci S. Tissue remodelling in liver diseases. Histol Histopathol 2003; 18: 1267-1274.

14. Fisher R. On the interpretation of X2 from contingency tables, and the calculation of P. J Royal Statist Soc 1922; 85: 87-94.

15. Lindley D. Regression and correlation analysis: New Palgrave, 1987.

16. Bergasa NV, Alling DW, Talbot TL, Swain MG, Yurdaydin C, Schmitt JM, Walker EC, et al. Naloxone ameliorates the pruritus of cholestasis: results of a double-blind randomized placebo-controlled trial. Annals of Internal Medicine 1995; 123: 161-167.

17. Zagon IS, Roesener CD, Verderame MF, Ohlsson-Wilhelm BM, Levin RJ, McLaughlin PJ. Opioid growth factor regulates the cell cycle of human neoplasias. Int J Oncol 2000; 17: 1053-1061.

18. Zagon IS, Verderame MF, Hankins J, McLaughlin PJ. Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells. Int J Oncol 2007; 30: 775-783.

19. Li Y, Zhang T, Douglas SD, Lai JP, Xiao WD, Pleasure DE, Ho WZ. Morphine enhances hepatitis C virus (HCV) replicon expression. Am J Pathol 2003; 163: 1167-1175.

20. Kapas S, Purbrick A, Hinson JP. Action of opioid peptides on the rat adrenal cortex: stimulation of steroid secretion through a specific mu opioid receptor. J Endocrinol 1995; 144: 503-510.

21. Alt A, Mansour A, Akil H, Medzihradsky F, Traynor JR, Woods JH. Stimulation of guanosine-5'-O-(3-[35S]thio)triphosphate binding by endogenous opioids acting at a cloned mu receptor. J Pharmacol Exp Ther 1998; 286: 282-288.

22. Bergasa NV, Boyella VD. Liver derived endogenous opioids may interfere with the therapeutic effect of interferon in chronic hepatitis C. Medical Hypotheses 2008;70:556-9 .

23. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology 2006; 44: 1675-1684.